Another important challenge of lung cancer therapy is the role of deregulated functioning of miR-23a and stem cells in making the lung cancer cells resistant to epidermal growth factor receptor-targeted tyrosine kinase inhibitors (EGFR-TKIs), commonly used for lung cancer treatment. The gene discussed is EGFR; the disease is lung cancer.